Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AFP 168; DE-085; DE-118; MK-2452; Saflutan; Taflotan; Tapros; Tapros mini ophthalmic solution 0.0015%; Tapros ophthalmic solution 0.0015%; Zioptan

Latest Information Update: 08 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santen Pharmaceutical
  • Developer Merck & Co; Santen Pharmaceutical
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 03 Jul 2017 Santen Oy completes a phase I trial in Glaucoma and Ocular hypertension (In children, In adolescent) in USA, Hungary, Slovakia, Poland and United Kingdom (NCT02102750)
  • 01 Apr 2016 Preservative-free formulation launched for Glaucoma and Ocular hypertension in Singapore (Santen pipeline, July 2016)
  • 01 Mar 2016 Launched for Ocular hypertension and Glaucoma in China (Ophthalmic) (Santen pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top